NEW YORK, NY / ACCESS Newswire / November 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Prelude Therapeutics Incorporated ("Prelude Therapeutics Incorporated") (NASDAQ:PRLD) concerning possible violations of federal securities laws.
Prelude issued a press release on November 4, 2025, announcing its decision to pause the clinical development of its SMARCA2 degrader program. Prelude said that "[t]he decision to pause was based on a comprehensive review of clinical data generated to date and the Company’s assessment of the capital and resource allocation required to advance the SMARCA2 program, versus the JAK2 and KAT6A programs, to key points of value inflection."
Following this news, Prelude’s stock price fell over 55% on November 4, 2025. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP
View the original press release on ACCESS Newswire
COMTEX_470162321/2457/2025-11-10T13:43:48